<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Springer Nature</publisher>
				<availability status="unknown"><p>Copyright Springer Nature</p>
				</availability>
				<date type="published" when="2012-05-29">29 May 2012</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Einama</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of General Surgery</orgName>
								<orgName type="department" key="dep2">Graduate School of Medicine</orgName>
								<orgName type="institution">Hokkaido University</orgName>
								<address>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Gastroenterological and General Surgery</orgName>
								<orgName type="department" key="dep2">Department of Surgery</orgName>
								<orgName type="institution">Asahikawa Medical University</orgName>
								<address>
									<settlement>Asahikawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Homma</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of General Surgery</orgName>
								<orgName type="department" key="dep2">Graduate School of Medicine</orgName>
								<orgName type="institution">Hokkaido University</orgName>
								<address>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Kamachi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of General Surgery</orgName>
								<orgName type="department" key="dep2">Graduate School of Medicine</orgName>
								<orgName type="institution">Hokkaido University</orgName>
								<address>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Kawamata</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of General Surgery</orgName>
								<orgName type="department" key="dep2">Graduate School of Medicine</orgName>
								<orgName type="institution">Hokkaido University</orgName>
								<address>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Takahashi</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Cancer Pathology</orgName>
								<orgName type="institution">Hokkaido University School of Medicine</orgName>
								<address>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Takahashi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of General Surgery</orgName>
								<orgName type="department" key="dep2">Graduate School of Medicine</orgName>
								<orgName type="institution">Hokkaido University</orgName>
								<address>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Taniguchi</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Gastroenterological and General Surgery</orgName>
								<orgName type="department" key="dep2">Department of Surgery</orgName>
								<orgName type="institution">Asahikawa Medical University</orgName>
								<address>
									<settlement>Asahikawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Kamiyama</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of General Surgery</orgName>
								<orgName type="department" key="dep2">Graduate School of Medicine</orgName>
								<orgName type="institution">Hokkaido University</orgName>
								<address>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Furukawa</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Gastroenterological and General Surgery</orgName>
								<orgName type="department" key="dep2">Department of Surgery</orgName>
								<orgName type="institution">Asahikawa Medical University</orgName>
								<address>
									<settlement>Asahikawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Matsuno</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Surgical Pathology</orgName>
								<orgName type="institution">Hokkaido University Hospital</orgName>
								<address>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Tanaka</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Cancer Pathology</orgName>
								<orgName type="institution">Hokkaido University School of Medicine</orgName>
								<address>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>Dr</roleName><forename type="first">H</forename><surname>Nishihara</surname></persName>
							<email>hnishihara@s5.dion.ne.jp</email>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Translational Pathology</orgName>
								<orgName type="department" key="dep2">Graduate School of Medicine</orgName>
								<orgName type="institution">Hokkaido University</orgName>
								<address>
									<addrLine>Kita-Ku, Kita 14, Nishi 7</addrLine>
									<postCode>060-8638</postCode>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Taketomi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of General Surgery</orgName>
								<orgName type="department" key="dep2">Graduate School of Medicine</orgName>
								<orgName type="institution">Hokkaido University</orgName>
								<address>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Todo</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of General Surgery</orgName>
								<orgName type="department" key="dep2">Graduate School of Medicine</orgName>
								<orgName type="institution">Hokkaido University</orgName>
								<address>
									<settlement>Sapporo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="institution">Hokkaido University Hospital</orgName>
								<address>
									<settlement>Sapporo</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer</title>
					</analytic>
					<monogr>
						<title level="j" type="main">British Journal of Cancer</title>
						<title level="j" type="abbrev">Br J Cancer</title>
						<idno type="ISSN">0007-0920</idno>
						<idno type="eISSN">1532-1827</idno>
						<imprint>
							<publisher>Springer Nature</publisher>
							<biblScope unit="volume">107</biblScope>
							<biblScope unit="issue">1</biblScope>
							<biblScope unit="page" from="137" to="142"/>
							<date type="published" when="2012-05-29">29 May 2012</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1038/bjc.2012.235</idno>
					<idno type="PMID">22644300</idno>
					<idno type="PMCID">PMC3389425</idno>
					<ptr type="open-access" target="https://www.nature.com/articles/bjc2012235.pdf" />
					<note type="submission">Received 6 February 2012; revised 25 April 2012; accepted 29 April 2012;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-13T22:57+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>mesothelin</term>
					<term>luminal membrane expression</term>
					<term>gastric cancer</term>
				</keywords>
			</textClass>
			<abstract>
				<p>BACKGROUND: Mesothelin is expressed in various types of malignant tumour, and we recently reported that expression of mesothelin was related to an unfavourable patient outcome in pancreatic ductal adenocarcinoma. In this study, we examined the clinicopathological significance of the mesothelin expression in gastric cancer, especially in terms of its association with the staining pattern. METHODS: Tissue specimens from 110 gastric cancer patients were immunohistochemically examined. The staining proportion and intensity of mesothelin expression in tumour cells were analysed, and the localisation of mesothelin was classified into luminal membrane and/or cytoplasmic expression. RESULTS: Mesothelin was positive in 49 cases, and the incidence of mesothelin expression was correlated with lymph-node metastasis. Furthermore, luminal membrane staining of mesothelin was identified in 16 cases, and the incidence of luminal membrane expression was also correlated with pT factor, pStage, lymphatic permeation, blood vessel permeation, recurrence, and poor patient outcome. Multivariate analysis showed that luminal membrane expression of mesothelin was an independent predictor of overall patient survival. CONCLUSION: We described that the luminal membrane expression of mesothelin was a reliable prognostic factor in gastric cancer, suggesting the functional significance of membrane-localised mesothelin in the aggressive behaviour of gastric cancer cells.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Mesothelin is a 40-kDa cell surface glycoprotein and is expressed on normal mesothelial cells lining the pleura, pericardium, and peritoneum <ref type="bibr" target="#b7">(Chang et al, 1992;</ref><ref type="bibr" target="#b6">Chang and Pastan, 1996)</ref>. Moreover, mesothelin is overexpressed in various types of malignant tumour, including malignant mesothelioma, ovarian cancer, and pancreatic cancer <ref type="bibr" target="#b0">(Argani et al, 2001;</ref><ref type="bibr">Ordonez, 2003a, b;</ref><ref type="bibr" target="#b16">Hassan et al, 2005a;</ref><ref type="bibr" target="#b10">Einama et al, 2011)</ref>. The full length of human mesothelin gene codes the primary product being a 71-kDa precursor protein. It can be physiologically cleaved by some furinlike proteases into a 40-kDa C-terminal fragment that remains membrane bound, and a 31-kDa N-terminal fragment, which is secreted into the blood <ref type="bibr" target="#b6">(Chang and Pastan, 1996)</ref>. The C-terminal 40-kDa fragment is named mesothelin and is attached to the cell membrane through a glycosyl-phosphatidylinositol (GPI) anchor <ref type="bibr" target="#b6">(Chang and Pastan, 1996;</ref><ref type="bibr" target="#b11">Hassan et al, 2004)</ref>.</p><p>The biological functions of mesothelin are not clearly understood, although recent studies have suggested that overexpression of mesothelin increases cell proliferation and migration . In ovarian cancers, diffuse mesothelin staining correlated significantly with prolonged survival in patients who had advanced-stage disease <ref type="bibr" target="#b25">(Yen et al, 2006)</ref>, and another report indicated that a higher mesothelin expression is associated with chemoresistance and shorter patient survival <ref type="bibr" target="#b9">(Cheng et al, 2009)</ref>. In pancreatic cancer, mesothelin expression was immunohistochemically observed in all cases, while its absence was noted in non-cancerous pancreatic ductal epithelium, with or without pancreatitis <ref type="bibr" target="#b0">(Argani et al, 2001;</ref><ref type="bibr" target="#b24">Swierczynski et al, 2004;</ref><ref type="bibr" target="#b17">Hassan et al, 2005b;</ref><ref type="bibr" target="#b10">Einama et al, 2011)</ref>. Furthermore, we recently explored that the expression of mesothelin was related to an unfavourable patient outcome in pancreatic ductal adenocarcinoma. However, in gastric cancer, which is one of the representative gastrointestinal cancers, mesothelin expression seems to correlate with prolonged patient survival <ref type="bibr" target="#b2">(Baba et al, 2011)</ref>; this is a paradoxical result for the other types of carcinomas. In this study, we investigated the immunohistochemical analysis of mesothelin in 110 primary gastric cancers, especially focussing in the localisation of mesothelin, that is, luminal membrane and/or cytoplasm, and its clinicopathological significance associated with patient's outcome.</p><p>Japan. The subjects of this study were 110 patients who underwent radical surgery for primary gastric cancer between 2002 and 2004 at the Department of General Surgery, Hokkaido University, Graduate School of Medicine, Sapporo, Japan. The clinicopathological characteristics of these cases are summarised in <ref type="table" target="#tab_0">Supplementary Table 1.</ref> Mean patient age was 62.1 years (±2.4 standard deviation (s.d.)). Seventy patients (63.6%) were men, and the remaining 40 (36.4%) were women. The location of the tumour was the upper third of the stomach in 38 (34.5%) patients and the middle and lower third in 72 (65.5%). Tumour stages comprising T factor, N factor, M factor, clinical stage were assigned according to the TNM classification of the Union Internationale Contre le Cancer <ref type="bibr" target="#b21">(Sobin and Wittekind, 2002)</ref>. Lymphatic permeation and blood vessel invasion were evaluated as either positive or negative. The median survival time of the patients was 54.8 months ( ± 5.2 s.d.).</p><p>Formalin-fixed paraffin-embedded tissue blocks were prepared from patient's tumour specimens, and sections were cut and stained with haematoxylin and eosin (HE) for routine histopathological examination. All specimens were diagnosed as gastric adenocarcinomas, and lymphatic permeation and blood vessel invasion were evaluated using Elastica van Gieson staining and immunostaining with anti-podoplanin (D2-40) antibody, if necessary, as a routine operation for pathological diagnosis. A representative tissue block including metastatic lymph node was selected from each case to perform immunohistochemical studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunohistochemistry</head><p>Four-micrometre-thick sections were mounted on charged glass slides, deparaffinised, and rehydrated through a graded ethanol series. For antigen retrieval, Dako Target Retrieval Solution pH 9.0 (Catalogue number S2368) was used, and the slides were boiled in a pressure cooker (Pascal Pressure Cooker, Model: S2800; DAKO JAPAN, Tokyo, Japan) to a temperature of 125 1C for 3 min. Endogeneous peroxidase was blocked with 0.3% hydrogen peroxidase. The slides were incubated with a 1 : 50 dilution of a mouse monoclonal antibody to mesothelin (clone 5B2 diluted 1 : 50; Novocastra, Newcastle Upon Tyne, UK) at room temperature for 30 min and then reacted with a dextran polymer reagent combined with secondary antibodies and peroxidase (Envision/ HRP; Dako) for 30 min at room temperature. Specific antigenantibody reactions were visualised with 0.2% diaminobenzine tetrahydrochloride and hydrogen peroxide. Slides were counterstained with haematoxylin for 10 min, then rinsed gently in reagent quality water.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunohistochemical evaluation</head><p>All assessments were made on the tumour region of the specimen ( Â 400). Each slide was evaluated independently by two pathologists (TE, KT) who did not know the clinical outcomes.</p><p>Immunostaining for mesothelin was evaluated for both the proportion and staining intensity of tumour cells in each case. The proportion of mesothelin expression was assessed according to the percentage of mesothelin-positive cells as follows: þ 1, 1-10%; þ 2, 10-50%; and þ 3, 450%. The staining intensity of mesothelin was evaluated as weak ( þ 1), moderate to strong ( þ 2) in addition to the staining localisation in the luminal membrane or in cytoplasm. The final evaluation of mesothelin expression was assessed using the following scoring system according to the previous study for the pancreas cancer <ref type="bibr" target="#b10">(Einama et al, 2011)</ref>: 'mesothelin positive' was defined as greater than or equal to þ 4 of proportion score and/or þ 2 of intensity score, while 'mesothelin negative' was given when the total score was less than þ 3 except in the cases of proportion score þ 1 and intensity score þ 2 ( <ref type="figure" target="#fig_0">Supplementary Figure 1)</ref>. Furthermore, among the 'mesothelin-positive' cases, the staining localisation of mesothelin was evaluated as luminal membrane and/or cytoplasm. In cases in which the entire circumference of the luminal membrane was explicitly stained even in partial throughout the section, 'luminal membrane positive' was given. When the luminal membrane was stained discontinuously and/or faintly, or in cases in which no membrane staining and only cytoplasmic staining was observed in any intensity level throughout the section, 'luminal membrane negative' was given ( <ref type="figure" target="#fig_0">Figure 1</ref>; <ref type="figure" target="#fig_0">Supplementary  Figure 1</ref>). Meanwhile, the mesothelin cytoplasmic expression was evaluated as follows: in a case in which the cytoplasmic staining was clearly observed in the constituent cancer cells, including the cytoplasmic granular staining, we judged it as 'cytoplasmic positive' <ref type="figure" target="#fig_0">(Figure 1</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>We used w 2 test or Fisher's exact test to determine the correlation between mesothelin and clinicopathological data. Survival curves of patients were drawn by the Kaplan-Meier method. Differences in survival curves were analysed by the log-rank test. Prognostic implications of mesothelin expression and clinicopathological parameters were analysed by Cox univariate and multivariate proportional hazards models. All differences were considered significant at a P-value of o0.05. All statistical analyses were performed using Statview 5.0 software (SAS Institute Inc., Cary, NC, USA).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinicopathological analysis for mesothelin expression</head><p>In the 110 gastric cancers, mesothelin expression was detected in 49 cases (44.5%), and the luminal membrane expression of  mesothelin was observed in 16 cases, while the cytoplasmic expression was detected in 42 tumours, which included the 9 cases of 'positive for both luminal membrane and cytoplasm' <ref type="figure" target="#fig_1">(Figure 2</ref>). The detailed clinicopathological information of 16 cases with mesothelin luminal membrane expression was summarised in <ref type="table" target="#tab_1">Supplementary Table 2</ref>. We never detected the mesothelin expression in the non-cancerous lesions (data not shown). The statistical analysis revealed that the incidence of mesothelin expression was only correlated with lymph-node metastasis (P ¼ 0.028), while the incidence of luminal membrane expression of mesothelin was correlated with pT factor (P ¼ 0.0019), lymphnode metastasis (P ¼ 0.0029), clinical stage (P ¼ 0.0002), lymphatic permeation (P ¼ 0.0019), blood vessel invasion (P ¼ 0.0098), and recurrence (Po0.0001). There were no significant correlations between mesothelin cytoplasmic expression and clinicopathological parameters <ref type="table" target="#tab_0">(Table 1)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival analysis associated with mesothelin expression</head><p>The analysis for patients' overall survival denoted that the group of 'luminal membrane positive' for mesothelin indicated a significantly unfavourable outcome compared with the group of 'luminal membrane negative' (Po0.001). On the other hand, the pure mesothelin expression regardless of the localisation, and also 'cytoplasmic expression' were not correlated with the overall survival of the patients <ref type="figure">(Figure 3)</ref>. To confirm the mesothelin expression as an independent prognostic factor, we performed the univariate analysis of the 110 gastric cancers using the Cox proportional hazards model, and obtained the result that pT factor, pN factor, clinical stage, lymphatic permeation, blood vessel invasion, and mesothelin luminal membrane expression were significantly correlated with the risk of cancer death <ref type="table" target="#tab_1">(Table 2)</ref>. Furthermore, to exclude the possible interference of any other factors, the multivariate analysis was performed including pT factor, pN factor, clinical stage, lymphatic permeation, blood vessel invasion, and mesothelin luminal membrane expression. Interestingly, the luminal membrane expression of mesothelin was an independent predictor of overall survival for gastric cancer patients as well as clinical stage and lymphatic permeation <ref type="table" target="#tab_2">(Table 3)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mesothelin expression in metastatic lymph nodes</head><p>As shown above, luminal membrane expression of mesothelin was correlated with lymphatic permeation and lymph-node metastasis; thus, we analysed the expression pattern of mesothelin in 35 out of 37 cases of lymph-node metastasis by immunohistochemistry, in which the tissue blocks of metastatic lymph node were available ( <ref type="figure" target="#fig_1">Supplementary Figure 2)</ref>. Interestingly, the incidence of luminal membrane positive including expression in both membrane and cytoplasm was increased in metastatic lymph nodes (51.4%; 18 out of 35) compared with primary lesions (31.4%; 11 out of 35). Moreover, in 4 cases out of 14 mesothelin-negative cases in primary lesion, luminal membrane expression of mesothelin was observed. These results support our idea that luminal membrane expression of mesothelin is associated with the malignant behaviour of tumour cells.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>In this study, we demonstrated that the luminal membrane expression of mesothelin in gastric cancer was associated with unfavourable clinical outcome in patients after surgery. The univariate analysis indicated that the luminal membrane expression of mesothelin was also correlated with lymph-node metastasis, clinical stage, lymphatic permeation, blood vessel invasion, residual tumour, and recurrence, although a luminal membrane expression of mesothelin remained a statistically independent factor for favourable patient outcome after the multivariate analysis. Our result that total mesothelin expression including the case of exclusive cytoplasmic expression did not correlate with patients' prognosis will explain the discrepant previous report in which mesothelin expression correlates with prolonged patient survival in gastric cancer <ref type="bibr" target="#b2">(Baba et al, 2011)</ref>. We therefore emphasise that membrane-localised mesothelin might have an important role in the development of gastric cancer. The full length of human mesothelin gene codes the primary product being a 71-kDa precursor protein. It can be  <ref type="figure">Figure 3</ref> Overall survival for patients with gastric cancer after surgical therapy stratified by the status of mesothelin expression (A), mesothelin luminal membrane expression (B), and mesothelin cytoplasmic expression (C), respectively. The group of 'luminal membrane positive' represented a statistically significantly unfavourable outcome compared with the group of 'luminal membrane negative' (B: Po0.001). On the other hand, both total expression (A) and cytoplasmic expression of mesothelin (C) were not correlated with overall survival of the patients.</p><p>physiologically cleaved by some furin-like proteases into a 40-kDa C-terminal fragment that remains membrane bound, and a 31-kDa N-terminal fragment, which is secreted into the blood <ref type="bibr" target="#b6">(Chang and Pastan, 1996)</ref>. The C-terminal 40-kDa fragment is referred to as mesothelin, which is attached to the cell membrane by a GPI anchor <ref type="bibr" target="#b6">(Chang and Pastan, 1996;</ref><ref type="bibr" target="#b11">Hassan et al, 2004)</ref>. The 5B2 antimesothelin antibody (Novocastra Laboratory Vision BioSystems, Boston, MA, USA), which we employed here for IHC, can detect the 71-kDa precursor protein and also the 40-kDa C-terminal fragment <ref type="bibr" target="#b20">(Inami et al, 2008)</ref>; therefore, we could not decide which form of mesothelin has a pivotal role in malignant behaviour of gastric cancer cells. Recent studies reported that mesothelin is not only associated with increased cell proliferation and with the migration of pancreatic cancer cells in vitro <ref type="bibr" target="#b3">(Bharadwaj et al, 2008;</ref>, but also contributes to tumour progression in vivo . Mesothelin inhibits paclitaxel-induced apoptosis through concomitant activation of phosphoinositide-3-kinase (PI3K) signalling in the regulation of Bcl-2 family expression <ref type="bibr" target="#b8">(Chang et al, 2009)</ref>, and induces the activation of signal transducer and activator of transcription (Stat) 3, which leads to increased expression of cyclin E and makes pancreatic cancer cells proliferate faster <ref type="bibr" target="#b3">(Bharadwaj et al, 2008)</ref>. In addition, mesothelin-activated nuclear factor-kappaB (NF-kB) induces elevated interleukin (IL)-6 expression, which acts as a growth factor to support pancreatic cancer cell survival/proliferation through a novel auto/paracrine IL-6/soluble IL-6R trans-signalling <ref type="bibr">(Bharadwaj et al, 2011a, b)</ref>. Our study provided a new aspect that luminal membrane expression of mesothelin is associated with the malignant behaviour of tumour cells, such as depth of tumour invasion and vascular invasion, although it remains necessary to clarify the biological function of the 71-kDa mesothelin precursor and/or 40-kDa mesothelin protein in in-vitro and in-vivo studies, including the processing system by furin-like proteases.</p><p>In terms of discovering the clinicopathological parameters for gastric cancer, there are many previous studies demonstrating the prognostic significance of various molecules, such as epidermal growth factor receptor and c-erB-2 (HER-2). These molecules also could be of unique significance as the indicators of eligibility to specific molecular targeting therapies, because most of them are located in the cell membrane as the useful targets for the molecular targeted drugs such as antibody drugs. We believe that the immunohistochemical evaluation for luminal membrane expression of mesothelin in gastric cancer would be of clinical benefit not only as a prognostic factor but also as a predictive factor for the eligibility to mesothelin-targeting therapies in the future <ref type="bibr" target="#b11">(Hassan et al, 2004</ref><ref type="bibr" target="#b12">(Hassan et al, , 2007a</ref><ref type="bibr" target="#b18">(Hassan et al, , b, c, 2010</ref><ref type="bibr" target="#b15">Hassan and Ho, 2008;</ref><ref type="bibr" target="#b19">Inami et al, 2009)</ref>.</p><p>In conclusion, we demonstrated the clinicopathological significance of the luminal membrane expression of mesothelin in gastric cancer as an independent prognostic factor, although additional studies to increase the number of the cases for luminal membrane expression (n ¼ 16) might be required for further confirmation. The immunohistochemical examination of mesothelin expression in surgically resected tumour specimens should be clinically useful for prognostication and for decision making about further treatment procedures after surgical therapy in patients with gastric cancer.</p><p>Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)  </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc>The expression variations of mesothelin and its cellular localisation in gastric cancer. (A, C, E, G, and I) HE stain. (B, D, F, H, and J) Immunohistochemical stain for mesothelin. (A and B) A case of 'mesothelin negative'. (C and D) A case of 'luminal membrane negative', although there was incomplete membrane staining in the cancer cells. (E and F) A case of 'luminal membrane positive'. The entire circumference staining of the cell membrane was stained. (G and H) A case of 'cytoplasmic positive' that represented the scant cytoplasmic staining of mesothelin. (I and J) A case of 'cytoplasmic positive' with granular staining in cancer cells. Scale bars: 100 mm.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc>Prognostic aspect depending on the expression pattern of mesothelin in gastric cancer Mesothelin expression (n = 110) Positive (n = 49)Positive; greater than 50% of tumour cells (proportion score of +3) or moderate to strong staining ( the intensity score of 2+) Flow chart of evaluation of mesothelin expression.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc>positive N = 16 P &lt; 0.001 (Logrank test) Cytoplasm positive N = 42 Cytoplasm negative N = 68 P = 0.985 (Logrank test)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc>Association between expression pattern of mesothelin and clinicopathological parameters</figDesc><table><row><cell></cell><cell></cell><cell cols="3">Mesothelin expression</cell><cell cols="3">Luminal membrane expression</cell><cell cols="3">Cytoplasmic expression</cell></row><row><cell></cell><cell></cell><cell>Positive</cell><cell>Negative</cell><cell></cell><cell>Positive</cell><cell>Negative</cell><cell></cell><cell>Positive</cell><cell>Negative</cell><cell></cell></row><row><cell>Parameter</cell><cell>Total</cell><cell>(n ¼ 49)</cell><cell>(n ¼ 61)</cell><cell>P-value</cell><cell>(n ¼ 16)</cell><cell>(n ¼ 94)</cell><cell>P-value</cell><cell>(n ¼ 42)</cell><cell>(n ¼ 68)</cell><cell>P-value</cell></row><row><cell cols="2">1. Histological classification</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>por2-sig</cell><cell>62</cell><cell>25</cell><cell>37</cell><cell>40.99</cell><cell>8</cell><cell>54</cell><cell>0.60</cell><cell>22</cell><cell>40</cell><cell>0.56</cell></row><row><cell>Others</cell><cell>48</cell><cell>24</cell><cell>24</cell><cell></cell><cell>8</cell><cell>40</cell><cell></cell><cell>20</cell><cell>28</cell><cell></cell></row><row><cell>2. pT factor</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pT1</cell><cell>62</cell><cell>23</cell><cell>39</cell><cell>0.085</cell><cell>3</cell><cell>59</cell><cell>0.0019</cell><cell>21</cell><cell>41</cell><cell>0.33</cell></row><row><cell>pT2-4</cell><cell>48</cell><cell>26</cell><cell>22</cell><cell></cell><cell>13</cell><cell>35</cell><cell></cell><cell>21</cell><cell>27</cell><cell></cell></row><row><cell>3. pN factor</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Positive</cell><cell>37</cell><cell>22</cell><cell>15</cell><cell>0.028</cell><cell>11</cell><cell>26</cell><cell>0.0029</cell><cell>17</cell><cell>20</cell><cell>0.30</cell></row><row><cell>Negative</cell><cell>73</cell><cell>27</cell><cell>46</cell><cell></cell><cell>5</cell><cell>68</cell><cell></cell><cell>25</cell><cell>48</cell><cell></cell></row><row><cell>4. pStage</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>I, II</cell><cell>80</cell><cell>34</cell><cell>46</cell><cell>0.52</cell><cell>5</cell><cell>75</cell><cell>0.0002</cell><cell>35</cell><cell>48</cell><cell>0.66</cell></row><row><cell>III, IV</cell><cell>30</cell><cell>15</cell><cell>15</cell><cell></cell><cell>11</cell><cell>19</cell><cell></cell><cell>10</cell><cell>20</cell><cell></cell></row><row><cell cols="2">5. Lymphatic permeation</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Positive</cell><cell>48</cell><cell>25</cell><cell>23</cell><cell>0.18</cell><cell>13</cell><cell>35</cell><cell>0.0019</cell><cell>20</cell><cell>28</cell><cell>0.56</cell></row><row><cell>Negative</cell><cell>62</cell><cell>24</cell><cell>38</cell><cell></cell><cell>3</cell><cell>59</cell><cell></cell><cell>22</cell><cell>40</cell><cell></cell></row><row><cell cols="2">6. Blood vessel permeation</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Positive</cell><cell>41</cell><cell>21</cell><cell>20</cell><cell>0.32</cell><cell>11</cell><cell>30</cell><cell>0.0098</cell><cell>16</cell><cell>25</cell><cell>40.99</cell></row><row><cell>Negative</cell><cell>69</cell><cell>28</cell><cell>41</cell><cell></cell><cell>5</cell><cell>64</cell><cell></cell><cell>26</cell><cell>43</cell><cell></cell></row><row><cell>7. Recurrence</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>26</cell><cell>14</cell><cell>12</cell><cell>0.37</cell><cell>11</cell><cell>15</cell><cell>o0.0001</cell><cell>9</cell><cell>17</cell><cell>0.82</cell></row><row><cell>No</cell><cell>84</cell><cell>35</cell><cell>49</cell><cell></cell><cell>5</cell><cell>79</cell><cell></cell><cell>33</cell><cell>51</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc>Univariate analysis for clinicopathological parameters and mesothelin expression on overall survival of patients with gastric carcinoma CI ¼ confidence interval. RR indicates relative risk/hazard ratio.</figDesc><table><row><cell>Factor</cell><cell>N</cell><cell>P</cell><cell>RR (95% CI)</cell></row><row><cell cols="2">1. Histological classification</cell><cell></cell><cell></cell></row><row><cell>por2-sig</cell><cell>62</cell><cell>0.89</cell><cell>1</cell></row><row><cell>Others</cell><cell>48</cell><cell></cell><cell>0.954 (0.478-1.903)</cell></row><row><cell>2. pT factor</cell><cell></cell><cell></cell><cell></cell></row><row><cell>pT1</cell><cell>62</cell><cell>o0.0001</cell><cell>1</cell></row><row><cell>pT2-4</cell><cell>48</cell><cell></cell><cell>13.354 (4.679-38.113)</cell></row><row><cell>3. pN factor</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Positive</cell><cell>73</cell><cell>o0.0001</cell><cell>1</cell></row><row><cell>Negative</cell><cell>37</cell><cell></cell><cell>9.301 (4.147-20.860)</cell></row><row><cell>4. pStage</cell><cell></cell><cell></cell><cell></cell></row><row><cell>I, II</cell><cell>80</cell><cell>o0.0001</cell><cell>1</cell></row><row><cell>III, IV</cell><cell>30</cell><cell></cell><cell>18.837 (8.032-44.179)</cell></row><row><cell cols="2">5. Lymphatic permeation</cell><cell></cell><cell></cell></row><row><cell>Positive</cell><cell>62</cell><cell>o0.0001</cell><cell>1</cell></row><row><cell>Negative</cell><cell>48</cell><cell></cell><cell>18.529 (5.637-60.534)</cell></row><row><cell cols="2">6. Blood vessel permeation</cell><cell></cell><cell></cell></row><row><cell>Positive</cell><cell>69</cell><cell>o0.0001</cell><cell>1</cell></row><row><cell>Negative</cell><cell>41</cell><cell></cell><cell>11.493 (4.722-27.971)</cell></row><row><cell cols="2">7. Mesothelin expression</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>61</cell><cell>o0.0001</cell><cell>1</cell></row><row><cell>Yes</cell><cell>49</cell><cell></cell><cell>1.749 (0.874-3.500)</cell></row><row><cell cols="2">8. Luminal membrane expression</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>94</cell><cell>o0.0001</cell><cell>1</cell></row><row><cell>Yes</cell><cell>16</cell><cell></cell><cell>7.205 (3.489-14.877)</cell></row><row><cell cols="2">9. Cytoplasmic expression</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>68</cell><cell>0.98</cell><cell>1</cell></row><row><cell>Yes</cell><cell>42</cell><cell></cell><cell>1.007 (0.493-2.055)</cell></row><row><cell>Abbreviation:</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc>Multivariate analysis for clinicopathological parameters and mesothelin expression on overall survival of patients with gastric carcinoma</figDesc><table><row><cell>Factor</cell><cell>P</cell><cell>RR (95% CI)</cell></row><row><cell>1. pT factor</cell><cell></cell><cell></cell></row><row><cell>pT1 vs pT2-4</cell><cell>0.35</cell><cell>2.497 (0.374-16.660)</cell></row><row><cell>2. pN factor</cell><cell></cell><cell></cell></row><row><cell>Positive vs Negative</cell><cell>0.060</cell><cell>3.532 (0.946-13.181)</cell></row><row><cell>3. pStage</cell><cell></cell><cell></cell></row><row><cell>I, II vs III, IV</cell><cell>0.0003</cell><cell>12.336 (2.533-60.069)</cell></row><row><cell>4. Lymphatic permeation</cell><cell></cell><cell></cell></row><row><cell>Positive vs Negative</cell><cell>0.0043</cell><cell>11.996 (2.180-65.996)</cell></row><row><cell>5. Blood vessel permeation</cell><cell></cell><cell></cell></row><row><cell>Positive vs Negative</cell><cell>0.29</cell><cell>2.091 (0.533-8.195)</cell></row><row><cell>6. Luminal membrane expression</cell><cell></cell><cell></cell></row><row><cell>No vs Yes</cell><cell>0.0073</cell><cell>2.969 (1.341-6.573)</cell></row></table><note>Abbreviation: CI ¼ confidence interval. RR indicates relative risk/hazard ratio.</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">British Journal of Cancer (2012) 107(1), 137 -142 &amp; 2012 Cancer Research UK</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">&amp; 2012 Cancer Research UK British Journal of Cancer (2012) 107(1), 137 -142</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Mesothelin in gastric cancer</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENTS</head><p>This work was supported in part by a grant-in-aid from the foundation for the Department of General Surgery, Hokkaido University Alumni Association.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Argani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Iacobuzio-Donahue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Ryu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Rosty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Goggins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Wilentz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">R</forename><surname>Murugesan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">D</forename><surname>Leach</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Jaffee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Yeo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Cameron</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">E</forename><surname>Kern</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Hruban</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2001" />
			<publisher>SAGE</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="3862" to="3868" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Mesothelin expression correlates with prolonged patient survival in gastric cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenji</forename><surname>Baba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sumiya</forename><surname>Ishigami</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takaaki</forename><surname>Arigami</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshikazu</forename><surname>Uenosono</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroshi</forename><surname>Okumura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masataka</forename><surname>Matsumoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroshi</forename><surname>Kurahara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuto</forename><surname>Uchikado</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshiaki</forename><surname>Kita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuko</forename><surname>Kijima</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masaki</forename><surname>Kitazono</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroyuki</forename><surname>Shinchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shinichi</forename><surname>Ueno</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shoji</forename><surname>Natsugoe</surname></persName>
		</author>
		<idno type="DOI">10.1002/jso.22024</idno>
		<idno type="PMID">21780126</idno>
		<idno type="ark">ark:/67375/WNG-6FV712CW-8</idno>
		<idno type="istexId">DCCAC789B2C72EEE3DD93CF032C7679E9A3AB57A</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Surgical Oncology</title>
		<title level="j" type="abbrev">J. Surg. Oncol.</title>
		<idno type="ISSN">0022-4790</idno>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="195" to="199" />
			<date type="published" when="2011-07-20" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Mesothelin-Induced Pancreatic Cancer Cell Proliferation Involves Alteration of Cyclin E via Activation of Signal Transducer and Activator of Transcription Protein 3</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Bharadwaj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Yao</surname></persName>
		</author>
		<idno type="DOI">10.1158/1541-7786.mcr-08-0095</idno>
		<idno type="PMID">19010822</idno>
		<idno type="PMCID">PMC2929833</idno>
		<ptr type="open-access" target="http://mcr.aacrjournals.org/content/6/11/1755.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Molecular Cancer Research</title>
		<title level="j" type="abbrev">Molecular Cancer Research</title>
		<idno type="ISSN">1541-7786</idno>
		<idno type="ISSNe">1557-3125</idno>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1755" to="1765" />
			<date type="published" when="2008-11-01" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Uddalak</forename><surname>Bharadwaj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christian</forename><surname>Marin-Muller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Min</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Changyi</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Qizhi</forename><surname>Yao</surname></persName>
		</author>
		<idno type="DOI">10.1186/1476-4598-10-106</idno>
		<idno type="PMID">21880146</idno>
		<idno type="PMCID">PMC3175472</idno>
		<ptr type="open-access" target="https://molecular-cancer.biomedcentral.com/track/pdf/10.1186/1476-4598-10-106" />
	</analytic>
	<monogr>
		<title level="j">Molecular Cancer</title>
		<title level="j" type="abbrev">Molecular Cancer</title>
		<idno type="ISSN">1476-4598</idno>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">106</biblScope>
			<date type="published" when="2011" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Mesothelin Overexpression Promotes Autocrine IL-6/sIL-6R Trans-Signaling to Stimulate Pancreatic Cancer Cell Proliferation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Bharadwaj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Marin-Muller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Yao</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jss.2009.11.450</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3128561?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Journal of Surgical Research</title>
		<title level="j" type="abbrev">Journal of Surgical Research</title>
		<idno type="ISSN">0022-4804</idno>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">335</biblScope>
			<date type="published" when="2010-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Pastan</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.93.1.136</idno>
		<idno type="PMID">8552591</idno>
		<idno type="PMCID">PMC40193</idno>
		<ptr type="open-access" target="http://www.pnas.org/content/93/1/136.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences</title>
		<title level="j" type="abbrev">Proceedings of the National Academy of Sciences</title>
		<idno type="ISSN">0027-8424</idno>
		<idno type="ISSNe">1091-6490</idno>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="136" to="140" />
			<date type="published" when="1996-01-09" />
			<publisher>Proceedings of the National Academy of Sciences</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kai</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ira</forename><surname>Pastan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><forename type="middle">C</forename><surname>Willingham</surname></persName>
		</author>
		<idno type="DOI">10.1002/ijc.2910500308</idno>
		<idno type="PMID">1735605</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Cancer</title>
		<title level="j" type="abbrev">Int. J. Cancer</title>
		<idno type="ISSN">0020-7136</idno>
		<idno type="ISSNe">1097-0215</idno>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="373" to="381" />
			<date type="published" when="1992-02-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ming-Cheng</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chi-An</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chang-Yao</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chien-Nan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi-Ning</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yu-Hao</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wen-Fang</forename><surname>Cheng</surname></persName>
		</author>
		<idno type="DOI">10.1042/bj20082196</idno>
		<idno type="PMID">19747165</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/1f87/764af8ca123a8d65253944cadfd676b4b456.pdf" />
	</analytic>
	<monogr>
		<title level="j">Biochemical Journal</title>
		<title level="j" type="abbrev">Biochem. J.</title>
		<idno type="ISSN">0264-6021</idno>
		<idno type="ISSNe">1470-8728</idno>
		<imprint>
			<biblScope unit="volume">424</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="449" to="458" />
			<date type="published" when="2009-12-15" />
			<publisher>Portland Press Ltd.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W-F</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C-Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M-C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-H</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-C</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C-Y</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C-A</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.bjc.6604964</idno>
		<idno type="PMID">19293794</idno>
		<idno type="PMCID">PMC2669998</idno>
		<ptr type="open-access" target="https://www.nature.com/articles/6604964.pdf" />
	</analytic>
	<monogr>
		<title level="j">British Journal of Cancer</title>
		<title level="j" type="abbrev">Br J Cancer</title>
		<idno type="ISSN">0007-0920</idno>
		<idno type="ISSNe">1532-1827</idno>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1144" to="1153" />
			<date type="published" when="2009-03-17" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Co-Expression of Mesothelin and CA125 Correlates With Unfavorable Patient Outcome in Pancreatic Ductal Adenocarcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takahiro</forename><surname>Einama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hirofumi</forename><surname>Kamachi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroshi</forename><surname>Nishihara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shigenori</forename><surname>Homma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiromi</forename><surname>Kanno</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenta</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ayami</forename><surname>Sasaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Munenori</forename><surname>Tahara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kuniaki</forename><surname>Okada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shunji</forename><surname>Muraoka</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Toshiya</forename><surname>Kamiyama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshihiro</forename><surname>Matsuno</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michitaka</forename><surname>Ozaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Satoru</forename><surname>Todo</surname></persName>
		</author>
		<idno type="DOI">10.1097/mpa.0b013e318221bed8</idno>
		<idno type="PMID">21775916</idno>
	</analytic>
	<monogr>
		<title level="j">Pancreas</title>
		<title level="j" type="abbrev">Pancreas</title>
		<idno type="ISSN">0885-3177</idno>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1276" to="1282" />
			<date type="published" when="2011-11" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Mesothelin: A New Target for Immunotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Bera</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Pastan</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.ccr-03-0801</idno>
		<idno type="PMID">15217923</idno>
		<ptr type="open-access" target="https://clincancerres.aacrjournals.org/content/clincanres/10/12/3937.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Cancer Research</title>
		<title level="j" type="abbrev">Clinical Cancer Research</title>
		<idno type="ISSN">1078-0432</idno>
		<idno type="ISSNe">1557-3265</idno>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3937" to="3942" />
			<date type="published" when="2004-06-15" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Anti Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">C</forename><surname>Broaddus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Liewehr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.ccr-07-1592</idno>
		<idno type="PMID">18056197</idno>
		<ptr type="open-access" target="http://clincancerres.aacrjournals.org/content/13/23/7166.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Cancer Research</title>
		<title level="j" type="abbrev">Clinical Cancer Research</title>
		<idno type="ISSN">1078-0432</idno>
		<idno type="ISSNe">1557-3265</idno>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="7166" to="7171" />
			<date type="published" when="2007-12-01" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Bullock</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Premkumar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Kreitman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Kindler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Willingham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Pastan</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.ccr-07-0869</idno>
		<idno type="PMID">17785569</idno>
		<ptr type="open-access" target="http://clincancerres.aacrjournals.org/content/13/17/5144.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Cancer Research</title>
		<title level="j" type="abbrev">Clinical Cancer Research</title>
		<idno type="ISSN">1078-0432</idno>
		<idno type="ISSNe">1557-3265</idno>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="5144" to="5149" />
			<date type="published" when="2007-09-01" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Ebel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">L</forename><surname>Routhier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">B</forename><surname>Kline</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Chao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Jacob</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Turchin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Gibbs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">D</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Mudali</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Iacobuzio-Donahue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">M</forename><surname>Jaffee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Moreno</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Pastan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">M</forename><surname>Sass</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">C</forename><surname>Nicolaides</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Grasso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immun</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">20</biblScope>
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Mesothelin targeted cancer immunotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raffit</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mitchell</forename><surname>Ho</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejca.2007.08.028</idno>
		<idno type="PMID">17945478</idno>
		<idno type="PMCID">PMC2265108</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2265108?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">European Journal of Cancer</title>
		<title level="j" type="abbrev">European Journal of Cancer</title>
		<idno type="ISSN">0959-8049</idno>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="46" to="53" />
			<date type="published" when="2008-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Localization of Mesothelin in Epithelial Ovarian Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raffit</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">J</forename><surname>Kreitman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ira</forename><surname>Pastan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><forename type="middle">C</forename><surname>Willingham</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.pai.00000141545.36485.d6</idno>
		<idno type="PMID">16082249</idno>
	</analytic>
	<monogr>
		<title level="j">Applied Immunohistochemistry &amp; Molecular Morphology</title>
		<title level="j" type="abbrev">Applied Immunohistochemistry &amp; Molecular Morphology</title>
		<idno type="ISSN">1541-2016</idno>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="243" to="247" />
			<date type="published" when="2005-09" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Mesothelin Is Overexpressed in Pancreaticobiliary Adenocarcinomas But Not in Normal Pancreas and Chronic Pancreatitis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raffit</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zoltan</forename><forename type="middle">G</forename><surname>Laszik</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Megan</forename><surname>Lerner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><surname>Raffeld</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Russell</forename><surname>Postier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><surname>Brackett</surname></persName>
		</author>
		<idno type="DOI">10.1309/f1b6-4cl7-h8vj-keaf</idno>
		<idno type="PMID">16416732</idno>
		<ptr type="open-access" target="https://academic.oup.com/ajcp/article-pdf/124/6/838/24984011/ajcpath124-0838.pdf" />
	</analytic>
	<monogr>
		<title level="j">American Journal of Clinical Pathology</title>
		<title level="j" type="abbrev">American Journal of Clinical Pathology</title>
		<idno type="ISSN">0002-9173</idno>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="838" to="845" />
			<date type="published" when="2005-12-01" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raffit</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Charles</forename><surname>Schweizer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kun</forename><forename type="middle">F</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Barbara</forename><surname>Schuler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alan</forename><forename type="middle">T</forename><surname>Remaley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><forename type="middle">C</forename><surname>Weil</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ira</forename><surname>Pastan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.lungcan.2009.07.016</idno>
		<idno type="PMID">19744744</idno>
		<idno type="PMCID">PMC2864325</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2864325?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<title level="j" type="abbrev">Lung Cancer</title>
		<idno type="ISSN">0169-5002</idno>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="455" to="459" />
			<date type="published" when="2010-06" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Koichi</forename><surname>Inami</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masaaki</forename><surname>Abe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kazuyoshi</forename><surname>Takeda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshiaki</forename><surname>Hagiwara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masahiro</forename><surname>Maeda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tatsuya</forename><surname>Segawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masafumi</forename><surname>Suyama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sumio</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Okio</forename><surname>Hino</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1349-7006.2009.01463.x</idno>
		<idno type="PMID">20100205</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Science</title>
		<idno type="ISSN">1347-9032</idno>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="969" to="974" />
			<date type="published" when="2009-12-09" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Inami</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kajino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Abe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Hagiwara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Maeda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Suyama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Hino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Rep</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1375" to="1380" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">H</forename><surname>Sobin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cw ; New York</forename><surname>Wittekind</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Bharadwaj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">E</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">C</forename><surname>Brunicardi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Yao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="286" to="296" />
			<date type="published" when="2002" />
			<publisher>Wiley-Liss</publisher>
		</imprint>
	</monogr>
	<note>TNM Classification of Malignant Tumors</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Application of Mesothelin Immunostaining in Tumor Diagnosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">G</forename><surname>Ordonez</surname></persName>
		</author>
		<idno type="DOI">10.1097/00000478-200311000-00003</idno>
		<idno type="PMID">14576474</idno>
	</analytic>
	<monogr>
		<title level="j">The American Journal of Surgical Pathology</title>
		<title level="j" type="abbrev">The American Journal of Surgical Pathology</title>
		<idno type="ISSN">0147-5185</idno>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1418" to="1428" />
			<date type="published" when="2003-11" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">G</forename><surname>Ordonez</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.mp.0000056981.16578.c3</idno>
		<idno type="PMID">12640097</idno>
		<ptr type="open-access" target="https://www.nature.com/articles/3880743.pdf" />
	</analytic>
	<monogr>
		<title level="j">Modern Pathology</title>
		<title level="j" type="abbrev">Mod Pathol</title>
		<idno type="ISSN">0893-3952</idno>
		<idno type="ISSNe">1530-0285</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="192" to="197" />
			<date type="published" when="2003-03" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sharon</forename><forename type="middle">L</forename><surname>Swierczynski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anirban</forename><surname>Maitra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><forename type="middle">C</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christine</forename><forename type="middle">A</forename><surname>Iacobuzio-Donahue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raheela</forename><surname>Ashfaq</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">L</forename><surname>Cameron</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">D</forename><surname>Schulick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Charles</forename><forename type="middle">J</forename><surname>Yeo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ayman</forename><surname>Rahman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">A</forename><surname>Hinkle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ralph</forename><forename type="middle">H</forename><surname>Hruban</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pedram</forename><surname>Argani</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.humpath.2003.10.012</idno>
		<idno type="PMID">15017593</idno>
	</analytic>
	<monogr>
		<title level="j">Human Pathology</title>
		<title level="j" type="abbrev">Human Pathology</title>
		<idno type="ISSN">0046-8177</idno>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="357" to="366" />
			<date type="published" when="2004-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Yen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">L</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">C</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Roden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shih</forename><surname>Ie</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.ccr-05-1397</idno>
		<idno type="PMID">16467095</idno>
		<ptr type="open-access" target="http://clincancerres.aacrjournals.org/content/12/3/827.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Cancer Research</title>
		<title level="j" type="abbrev">Clinical Cancer Research</title>
		<idno type="ISSN">1078-0432</idno>
		<idno type="ISSNe">1557-3265</idno>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="827" to="831" />
			<date type="published" when="2006-02-01" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3</title>
		<imprint/>
	</monogr>
	<note>This work is published under the standard license to publish agreement. Unported License</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
